1266237-82-4

Basic information

• Product Name: N-methyl-N'-[1-(2,4,6-trifluoro-phenyl)-meth-(E)-ylidene]-hydrazine
• Synonyms: N-methyl-N'-[1-(2,4,6-trifluoro-phenyl)-meth-(E)-ylidene]-hydrazine
• CAS NO: 1266237-82-4
• Molecular Weight: 188.152
• Mol File: 1266237-82-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-methyl-N'-[1-(2,4,6-trifluoro-phenyl)-meth-(E)-ylidene]-hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-N'-[1-(2,4,6-trifluoro-phenyl)-meth-(E)-ylidene]-hydrazine(1266237-82-4)
• EPA Substance Registry System: N-methyl-N'-[1-(2,4,6-trifluoro-phenyl)-meth-(E)-ylidene]-hydrazine(1266237-82-4)

Safety Data

• Hazardous Substances Data: 1266237-82-4(Hazardous Substances Data)

Upstream product

• 60-34-4 methylhydrazine 
• 58551-83-0 2,4,6-trifluorobenzaldehyde 

Downstream Products

• 1329166-90-6 4,6-difluoro-1-methyl-1H-indazole-5-carboxylic acid 

Relevant articles and documents

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).